Chapter review

Fitzgerald PMHNP board review. ch11. Substance-related Disorders. This is drive 8 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Management Strategies & Safety Items. Topic. Motivational Interviewing (MI) Principles. Bottom Line Summary. - **Motivational interviewing core goal**: **First-line** psychotherapy approach in substance use disorders to explore ambivalence, reduce resistance, and elicit internal motivation for change. - **Prochaska precontemplation stage**: Patient is in denial with zero recognition of a problem; PMHNP uses non-judgmental reflective listening and supportive empathy to build rapport. - **Prochaska contemplation stage**: Patient acknowledges problem but feels ambivalent; PMHNP guides discussion of pros and cons of substance use versus sobriety. - **OARS communication framework**: Open-ended questions, affirmations, reflective listening, and summaries form the foundation of non-confrontational engagement. - **Diagnostic criteria threshold**: **Substance use disorder** requires 2 or more of 11 criteria within 12 months (2 to 3 = mild, 4 to 5 = moderate, 6 or more = severe). - **Billing requirement**: Motivational interviewing counseling sessions exceeding 16 minutes can be billed alongside routine medication management appointments. - **Relapse prevention strategy**: Relapse prevention emphasizes social skills training, contingency contracting, and relaxation techniques, while avoiding high-risk peer confrontations. High-Yield Concept Review: Motivational Interviewing. Core Principles and Clinical Execution. Motivational interviewing (MI) is a person-centered, directive counseling style designed to address ambivalence toward behavior change. Patients presenting with substance use disorders often exhibit cognitive denial, defined as minimizing consequences, ignoring functional decline, or insisting outside treatment is unneeded. Instead of confronting denial directly, the PMHNP uses reflective listening to validate emotions and reframe patient statements. Direct confrontation escalates resistance and destroys the therapeutic alliance. **First-line** communication strategies rely on the OARS framework: - Open-ended questions that encourage patients to elaborate on their experiences. - Affirmations that recognize patient strengths and past successes. - Reflective listening that restates feelings and ambivalence back to the patient. - Summaries that tie together patient statements and highlight internal change talk. Matching MI to Prochaska Stages of Change. Matching clinical interventions to the patient's stage of readiness is essential on board exams. Precontemplation - **Think**: Patient sees no problem and remains in denial. - **Priority**: Build therapeutic alliance and deliver non-judgmental reflective statements. - **Boards are testing**: Avoiding premature push for action or confrontation. Contemplation - **Think**: Patient recognizes consequences but feels torn about quitting. - **Priority**: Explore pros and cons of continued use versus sobriety. - **Boards are testing**: Drawing out the patient's own arguments for change. Preparation and Action - **Think**: Patient commits to change and seeks an active plan. - **Priority**: Select specific modalities, set dates, and discuss pharmacotherapy options like **acamprosate** or **naltrexone**. - **Boards are testing**: Choosing concrete, structured interventions. Key Board Traps and Safety Alerts. **Board trap**: Confronting active drug-using peers for closure. Test writers often present peer confrontation as a step toward emotional closure. On the exam, this is always incorrect. Sending a patient in early recovery to confront former drug-using peers creates severe psychological stress, triggers intense cravings, and exposes the patient to active substance environments. **Safety alert**: Premature confrontation during severe denial. Confronting a patient who is in active denial increases defensiveness and causes treatment drop-out. Always prioritize safety assessment, rule out acute intoxication or withdrawal, and use empathetic reflection before proposing behavioral changes. Compare and Distinguish. Reflective Listening vs. Direct Confrontation. - **Do not confuse**: Empathetic validation with agreeing with harmful behavior. - **Think reflective listening when**: Patient expresses ambivalence or denial regarding substance use. - **Think direct confrontation when**: Never on board exams; direct confrontation causes resistance. - **Priority difference**: Reflective listening builds trust and elicits change talk; confrontation destroys alliance. - **What boards are really testing**: Ability to respond with advanced practice therapeutic communication rather than judgmental lecturing. Precontemplation vs. Contemplation Interventions. - **Do not confuse**: Strategy for a patient who sees no problem with one who is on the fence. - **Think precontemplation when**: Patient blames external factors like law school, advisor, or family for substance-related consequences. - **Think contemplation when**: Patient states "I know I should stop, but drinking helps me sleep." - **Priority difference**: Precontemplation requires rapport building and reflection; contemplation requires exploring pros and cons. - **What boards are really testing**: Selecting stage-matched psychotherapy techniques. Board-Style Practice Question Bank. Question 1. Marcus, a 24-year-old student at risk for failing out of law school, is referred by his academic advisor for psychiatric evaluation. He states that he drinks an average of 6 beers per night, and last year he had a driving under the influence (DUI) arrest. Marcus states, "I don't think my beer drinking has anything to do with my bad grades. I really only have a couple of beers every night, and it helps me to relax." This statement is an example of: A) Enabling B) Projection C) Psychological dependence D) Denial Pause. Answer: D. Quick Answer. Marcus's statement demonstrates denial by minimizing his alcohol consumption and denying its connection to his academic and legal problems. Key Clue. "I don't think my beer drinking has anything to do with my bad grades." Best Answer. D) Denial Why It Is Correct. Denial is a defense mechanism characterized by believing that substance use is not causing problems, minimizing negative consequences, or insisting that treatment is unnecessary despite objective evidence like failing grades and a DUI arrest [1-4]. Why the Other Choices Are Wrong. - **A**: Enabling occurs when family members or friends protect the individual from the natural consequences of their substance use. - **B**: Projection involves attributing one's own unacknowledged, unacceptable feelings or impulses onto another person. - **C**: Psychological dependence is characterized by intense cravings, emotional desire to use, or using substances to manage unpleasant mood states [5, 6]. Test-Taking Pearl. When a patient minimizes obvious legal or functional consequences of substance use, identify denial as the primary defense mechanism [1, 2, 4]. Question 2. The PMHNP's response to Marcus that best illustrates motivational interviewing would be: A) Relaxing is important to you after you've worked hard at school. B) Do you see your DUI as an indication that you likely have a problem with alcohol? C) Your advisor obviously thinks that your beer drinking is affecting your grades, and that is why he referred you here. D) What else could be causing your low grades then? Pause. Answer: A. Quick Answer. Option A applies motivational interviewing by using reflective listening to validate the patient's underlying desire to relax without judgment [7-9]. Key Clue. Empathy statement that reflects the patient's feelings and acknowledges perceived benefits without initiating an argument [8-10]. Best Answer. A) Relaxing is important to you after you've worked hard at school. Why It Is Correct. Motivational interviewing uses reflective statements to acknowledge the positive aspects or perceived benefits the patient finds in their behavior, establishing empathy and rapport so ambivalence can be safely explored later [8-10]. Why the Other Choices Are Wrong. - **B**: Asking a closed-ended question about his DUI directly challenges the patient, increasing resistance and provoking defensiveness source 9. - **C**: Referring back to the advisor's opinion externalizes the issue and creates an "us versus them" dynamic that harms rapport [8, 9]. - **D**: Using a challenging or sarcastic question provokes argument and shuts down collaborative exploration of change source 9. Test-Taking Pearl. Motivational interviewing answers on board exams always feature non-judgmental, reflective, or open-ended phrasing that meets the patient where they are [8, 10]. Question 3. Strategies to prevent relapse among patients with substance use disorders include all of the following EXCEPT: A) Relaxation techniques to address increased craving B) Confront drug using peers for closure C) Social skills training D) Give positive feedback for sustained abstinence, even with a relapse Pause. Answer: B. Quick Answer. Confronting drug-using peers for closure is NOT a valid relapse prevention strategy and increases risk of relapse [11-13]. Key Clue. The word "EXCEPT" requires identifying the unsafe or inappropriate intervention. Best Answer. B) Confront drug using peers for closure Why It Is Correct. Confronting former drug-using peers is unnecessary, exposes the patient in recovery to high-risk environments and peer pressure, and increases stress that can trigger immediate relapse [12, 14, 15]. Why the Other Choices Are Wrong. - **A**: Relaxation techniques help manage stress and autonomic hyperarousal associated with intense cravings [12, 15]. - **C**: Social skills training provides behavioral tools to refuse substances and manage interpersonal pressure safely [12, 16]. - **D**: Offering positive feedback reinforces progress and builds self-efficacy, helping maintain engagement even after a slip [12, 13]. Test-Taking Pearl. Relapse prevention on boards focuses on avoiding triggers, building coping skills, and providing supportive positive reinforcement, never on seeking high-stress personal confrontations [12, 14, 16]. Next. Topic. Board Trap: 'Compliance' vs 'Adherence'. Compliance vs Adherence in Substance-Related Disorders. Bottom Line Summary. * **Compliance** implies passive patient submission to provider authority, whereas **adherence** reflects a collaborative partnership achieved through **motivational interviewing**. * **Denial** is a primary cognitive defense mechanism where a patient minimizes substance consequences or denies needing help, such as drinking six beers nightly while blaming academic failure on outside sources. * **First-line** communication for addressing ambivalence and denial is **motivational interviewing**, utilizing reflective listening and empathy rather than direct confrontation. * **Acamprosate** is the **first-line** craving reduction agent for patients with moderate to severe liver disease because it is excreted renally, unlike **naltrexone** which carries a risk of hepatotoxicity. * **Naltrexone** blocks endogenous opioid receptors to reduce alcohol cravings, but it is strictly contraindicated in patients taking **opioids** or expecting upcoming surgical pain management within one month. * **Disulfiram** is an aversion therapy causing a severe aldehyde reaction with alcohol, but it is not initial therapy and is contraindicated with concurrent **metronidazole** use. * **Relapse prevention** utilizes **contingency contracting** (such as gift card rewards for negative urine screens in **methamphetamine** use disorder) and **social skills training**, while avoiding confrontation with drug-using peers. * **Delirium tremens** history is the single most prominent risk factor favoring inpatient hospitalization for acute alcohol withdrawal rather than outpatient detoxification. Core Teaching: Compliance, Adherence, and Management Strategies. **Board trap**: Test writers frequently try to trick candidates into choosing authoritative, confrontational, or scolding responses when a patient displays **denial** or poor treatment participation [1, 2]. Framing patient behavior as non-compliant leads clinicians to force compliance through direct confrontation, which escalates resistance and destroys the therapeutic alliance [3, 4]. On board exams, direct confrontation is always a distractor source 3. The correct approach is **motivational interviewing**, which uses open-ended questions, affirmations, reflective listening, and summarizing to explore ambivalence [3, 5, 6]. **First-line**: The **first-line** intervention for exploring ambivalence and building rapport in substance use disorders is **motivational interviewing** [3, 6]. Clinicians must meet patients at their current stage of change (pre-contemplation, contemplation, preparation, action, or maintenance) rather than forcing premature action steps [6, 7]. **Safety alert**: Provider prescribing choices must account for co-occurring physical disease and medical procedures [8, 9]. For alcohol use disorder craving management, **naltrexone** is contraindicated in acute hepatitis or liver failure, as well as in patients taking **opioids** or anticipating opioid administration (such as upcoming dental surgery), because blocking opioid receptors will trigger acute withdrawal or block necessary analgesia [10-12]. In patients with liver impairment, **acamprosate** is the safe **first-line** choice because it restores GABA and glutamate balance and is cleared renally [13, 14]. Spoken Teaching Review. Pharmacological agents for alcohol dependence: * **Acamprosate** restores GABA and glutamate balance to maintain abstinence source 13. It is excreted mainly by the kidneys, making it safe in liver disease, but requires dose adjustment in renal insufficiency source 13. * **Naltrexone** blocks endogenous opioid release to decrease the alcohol high and cravings [10, 15]. It is available as a daily oral tablet or a monthly long-acting injection (**Vivitrol**) source 10. It is contraindicated in acute hepatitis, liver failure, or concurrent opioid use source 10. * **Disulfiram** inhibits aldehyde dehydrogenase to cause an aversion reaction (nausea, flushing, tachycardia) if alcohol is consumed source 9. It is not initial therapy and is contraindicated with **metronidazole** or hidden alcohol sources source 9. Relapse prevention strategies: * Behavioral and cognitive interventions include relaxation techniques for cravings, **contingency contracting** (highly effective for **methamphetamine** use disorder using gift card incentives for negative drug screens), and structured **social skills training** to rebuild impaired interpersonal functioning [16-22]. * Patient safety guidance: Patients should be counseled to avoid drug-using peers and drug cues rather than confronting former drug-using peers for closure, which increases relapse risk [21, 23]. Fitzgerald Sample Questions. Question 1. Marcus, a 24-year-old student at risk for failing out of law school, is referred by his academic advisor for psychiatric evaluation source 24. He states that he drinks an average of six beers per night, and last year he had a driving under the influence (DUI) arrest source 24. Marcus states, "I don't think my beer drinking has anything to do with my bad grades. I really only have a couple of beers every night, and it helps me to relax" [2, 24]. This statement is an example of: * A) Enabling * B) Projection * C) Psychological dependence * D) Denial Pause. Answer: D Why it is correct: Marcus is demonstrating **denial**, which is the cognitive defense mechanism where an individual minimizes the consequences of their substance use, believes it causes no operational problems, or insists outside help is unnecessary despite objective evidence like failing grades and a DUI arrest [1, 2]. Why the other choices are wrong: * A: Enabling refers to actions taken by family members or peers that inadvertently allow the individual to continue substance use without experiencing consequences. * B: Projection involves attributing one's own unacceptable thoughts or urges onto another person. * C: Psychological dependence involves emotional cravings and a strong desire to use a substance to regulate mood, which does not define his minimization statement [1, 25]. Test-taking pearl: When a stem describes a patient minimizing clear substance-related consequences, recognize **denial** as the primary barrier to treatment source 1. Concept tested: Defense mechanisms in substance use disorders. Question 2. The PMHNP's response to Marcus that best illustrates **motivational interviewing** would be: * A) "Relaxing is important to you after you have worked hard at school." * B) "Do you see your DUI as an indication that you likely have a problem with alcohol?" * C) "Your advisor obviously thinks that your beer drinking is affecting your grades, and that is why he referred you here." * D) "What else could be causing your low grades then?" Pause. Answer: A Why it is correct: **Motivational interviewing** relies on empathetic reflection and validating the patient's subjective experience to explore ambivalence without provoking resistance [3, 4]. Reflecting that "relaxing is important to you" acknowledges the patient's perspective and builds rapport [3, 5]. Why the other choices are wrong: * B: Asking direct confrontational questions about a DUI forces the patient into a defensive stance and increases resistance source 4. * C: Shifting focus to the advisor's opinion invalidates the patient and creates an adversarial provider-patient dynamic source 4. * D: Asking a challenging question about low grades puts the patient on trial rather than exploring their ambivalence source 4. Test-taking pearl: Choose options that reflect empathy, validate feelings, and roll with resistance rather than direct confrontation or scolding [3, 4]. Concept tested: **Motivational interviewing** communication techniques. Question 3. Gary, a 54-year-old man with moderate liver disease, has a history of alcohol use disorder but has been abstinent for the past three and a half years [26, 27]. At this visit, he reports a number of unfortunate events that have happened recently, including the death of a close sibling and loss of employment source 27. As a result, he states that he is having increased urges to drink again source 27. The PMHNP realizes that: * A) The risk of relapse is minimal since he has established a long period of sobriety. * B) Stressful life events can be a trigger for a relapse. * C) He should be hospitalized immediately to prevent a possible relapse. * D) Limiting alcohol consumption to 2 to 3 drinks per day is acceptable. Pause. Answer: B Why it is correct: Major life stressors, grief, and employment loss are well-established high-risk triggers for relapse, even in individuals with long-standing sustained sobriety [28, 29]. Why the other choices are wrong: * A: Sobriety length reduces baseline risk, but major acute life stressors significantly increase relapse vulnerability at any stage source 29. * C: Hospitalization is restrictive and unnecessary for simple urges without active severe intoxication, withdrawal, or safety hazards source 30. * D: Recommending moderate drinking to a patient in recovery for alcohol use disorder violates the treatment goal of abstinence and increases relapse risk [30, 31]. Test-taking pearl: Recognize major life transitions and losses as critical triggers requiring proactive relapse prevention adjustments [28, 29]. Concept tested: Relapse triggers in long-term recovery. Question 4. To prevent a possible relapse by Gary, who has moderate liver disease, the PMHNP recommends counseling and treatment with: * A) Acamprosate * B) Naloxone * C) Clonidine * D) Lorazepam Pause. Answer: A Why it is correct: **Acamprosate** is the preferred pharmacotherapy for maintaining abstinence and reducing alcohol cravings in patients with liver disease because it is metabolized and excreted by the kidneys, avoiding hepatic toxicity [13, 14]. Why the other choices are wrong: * B: Naloxone is an acute opioid reversal agent used for overdose, not a treatment for alcohol cravings source 32. * C: Clonidine is an alpha-2 agonist used off-label for sympathetic withdrawal symptoms, not long-term craving reduction [14, 33]. * D: Lorazepam is a benzodiazepine used for acute alcohol withdrawal detoxification, not long-term relapse prevention due to addiction potential [14, 34]. Test-taking pearl: Match the anti-craving drug to organ function. Select **acamprosate** for liver disease and **naltrexone** when renal clearance is impaired [10, 13]. Concept tested: Pharmacotherapy for alcohol dependence with hepatic comorbidity. Question 5. Randy, a 32-year-old single manager of a sporting goods store, is being seen for follow-up after a 30-day inpatient stay for alcohol dependence [35, 36]. He has been sober for 45 days and continues to crave alcohol throughout the day source 36. Which medication can be prescribed for Randy as part of his treatment recovery plan to target alcohol cravings? * A) Disulfiram * B) Bupropion * C) Naltrexone * D) Naloxone Pause. Answer: C Why it is correct: **Naltrexone** is an opioid receptor antagonist specifically indicated to decrease alcohol cravings and block the intoxicating reinforcement of alcohol [15, 37]. Why the other choices are wrong: * A: Disulfiram is an aversion therapy that causes a physical reaction when alcohol is consumed, but it does not directly eliminate physiological cravings source 9. * B: Bupropion is an NDRI indicated for major depression and smoking cessation, not alcohol craving reduction. * D: Naloxone is a short-acting emergency opioid antagonist used exclusively for acute overdose reversal source 32. Test-taking pearl: Differentiate anti-craving agents (**naltrexone**, **acamprosate**) from aversion agents (**disulfiram**) [9, 13, 15]. Concept tested: First-line pharmacotherapy for alcohol cravings. Question 6. Dana, a 44-year-old registered nurse, is preparing to be discharged from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence source 37. She wishes to start a medication to help keep her abstinent from alcohol source 37. She has extensive dental work planned to begin within the next month source 11. Which medication would be contraindicated for use given this information? * A) Disulfiram * B) Naltrexone * C) Acamprosate * D) Sertraline Pause. Answer: B Why it is correct: **Naltrexone** blocks opioid receptors and is strictly contraindicated in patients who will require opioid analgesics for upcoming procedures (such as major dental surgery), as it would block pain relief or precipitate acute withdrawal if opioids are administered [10-12]. Why the other choices are wrong: * A: Disulfiram does not interact with opioid analgesics and is not contraindicated for upcoming dental surgery source 12. * C: Acamprosate does not affect opioid pathways and can be safely co-administered if pain control is required source 12. * D: Sertraline is an SSRI antidepressant that does not block opioid receptors, though it is not an anti-craving agent source 12. Test-taking pearl: Always screen for scheduled surgeries or procedures requiring opioid analgesia before initiating **naltrexone** [10, 12]. Concept tested: Contraindications to **naltrexone** therapy. Question 7. Strategies to prevent relapse among patients with substance use disorders include all of the following EXCEPT: * A) Relaxation techniques to address increased craving * B) Confronting drug-using peers for closure * C) Social skills training * D) Giving positive feedback for sustained abstinence, even without relapse Pause. Answer: B Why it is correct: Seeking out or confronting former drug-using peers creates severe environmental drug cues and high-risk relapse triggers, directly violating relapse prevention principles [21, 23]. Why the other choices are wrong: * A: Teaching relaxation techniques provides adaptive coping mechanisms for managing acute cravings [16, 22]. * C: **Social skills training** addresses interpersonal deficits and builds refusal skills necessary to maintain sobriety [20, 22]. * D: Offering positive reinforcement validates patient effort and reinforces long-term recovery behaviors [21, 22]. Test-taking pearl: Relapse prevention strategies focus on avoiding drug cues and peers rather than seeking confrontation [21, 23]. Concept tested: Relapse prevention and behavioral interventions. Question 8. When deciding on a treatment setting to manage withdrawal symptoms for a 46-year-old man with a history of alcohol use disorder, which of the following factors is most prominent in favoring hospitalization? * A) A CIWA score of less than 15 * B) A history of alcohol use disorder for over two years * C) A history of major depressive disorder * D) A prior history of delirium tremens Pause. Answer: D Why it is correct: A personal history of **delirium tremens** or withdrawal seizures is the single strongest clinical indicator requiring inpatient medical hospitalization due to high mortality risk and severe autonomic instability [38-40]. Why the other choices are wrong: * A: A CIWA score under 15 indicates mild to moderate withdrawal that can be managed safely in an outpatient setting [41-43]. * B: Chronicity of alcohol use alone does not automatically require inpatient admission without active severe withdrawal or DT history [38, 43]. * C: Co-occurring depression requires monitoring, but without acute active suicidality or severe withdrawal, it does not dictate medical detox hospitalization [43, 44]. Test-taking pearl: Prior **delirium tremens** or withdrawal seizures equal mandatory inpatient medical detoxification [38, 40]. Concept tested: Level of care selection for alcohol withdrawal. Next Study Step. * **Recommended Topic**: Fitzgerald Chapter 12: Personality Disorders. * **Why this is the best next step**: Master Cluster B personality traits (such as Borderline and Antisocial personality disorders) to build directly on substance use management, addressing common co-occurring behavioral patterns, splitting, manipulation, boundary setting, and crisis interventions on board exams. 💡 Want to do a rapid-fire active recall session on alcohol withdrawal protocols (CIWA) or test your knowledge on Cluster B personality disorder board traps next? Next. New section. Case Reviews & Fitzgerald Questions. Topic. Review Question: Denial Definition. Bottom Line Summary. - **Substance dependence** can occur with or without **physical dependence**. - **Physical dependence** requires demonstrated physiological **tolerance** or **withdrawal**. - **Psychological dependence** involves emotional cravings and using a substance to avoid unpleasant mood states. - **Denial** is a primary cognitive defense mechanism where patients minimize consequences, claim substance use causes no impairment, or refuse outside help. - **CAGE questionnaire** uses 2 or more positive responses (sensitivity 93%, specificity 76%) to screen for problematic drinking and **withdrawal** risk. - **AUDIT questionnaire** uses 10 items to identify problem drinking before **withdrawal** develops, especially in college students, women, and minorities. - **Motivational interviewing** employs empathetic reflective statements to address ambivalence rather than confronting **denial**. Core Clinical Concepts. Definitions of Dependence and Denial. - **Substance dependence**: Repeated chemical or drug use where **physical dependence** may be absent or present. - **Physical dependence**: Characterized by physiological **tolerance** (needing increased amounts to achieve desired effect) and **withdrawal** symptoms upon stopping. - **Psychological dependence**: Characterized by compulsive craving, strong desire to use, and taking the drug to escape low or unpleasant mood states. - **Denial**: A core cognitive defense mechanism where the patient believes substance use causes no disruption, minimizes usage, or insists outside treatment is unnecessary. Clinical Assessment and Screening. - **First-Line** screening approach: Ask open-ended questions like "How much alcohol do you drink?" instead of closed yes or no items, because patients in **denial** frequently underreport consumption. - Collateral information: Obtain history from family members or case managers to establish accurate quantity and frequency. - **CAGE questionnaire**: 4 items assessing **Cut down**, **Annoyed**, **Guilty**, and **Eye-opener**. 2 or more positive answers indicate problematic drinking with 93% sensitivity and 76% specificity. - **AUDIT questionnaire**: 10 items useful for detecting problem drinking in college students, women, and minorities before physical **withdrawal** occurs. Signposts and Exam Pearls. - **Safety Alert**: **Denial** blinds patients to severe physical and legal risks, such as driving while impaired or failing academic programs. Always assess immediate physical safety, suicidal ideation, and domestic safety during evaluations. - **Board Trap**: Do not confront a patient in **denial** directly or argue about their substance use. Direct confrontation increases resistance and destroys the therapeutic alliance. - **First-Line**: Use **motivational interviewing** to explore ambivalence, validate feelings, and reflect patient statements out loud to build rapport and foster internal motivation. Sample Board Questions. Question 1. Stem: Marcus, a 24-year-old student at risk for failing out of law school, is referred by his academic advisor for psychiatric evaluation. He states that he drinks an average of 6 beers per night, and last year he had a driving under the influence (DUI) arrest. Marcus states, "I don't think my beer drinking has anything to do with my bad grades. I really only have a couple of beers every night, and it helps me to relax." This statement is an example of: - A. enabling - B. projection - C. psychological dependence - D. denial Pause. Answer: D. Why correct: Marcus exhibits **denial** by minimizing his daily intake from six beers to a couple, downplaying his DUI arrest, and refusing to connect heavy drinking with his academic failure. Why distractors fail: - A. **Enabling** is incorrect because enabling is an action taken by another person, such as a family member or partner, that protects the individual from experiencing the consequences of their substance use. - B. **Projection** is incorrect because projection involves attributing one's own unacceptable impulses, feelings, or thoughts onto another person. - C. **Psychological dependence** is incorrect because psychological dependence refers to internal emotional cravings and using a substance to avoid unpleasant mood states, whereas minimizing consequences and rejecting impairment is **denial**. Question 2. Stem: The PMHNP's response to Marcus that best illustrates motivational interviewing would be: - A. "Relaxing is important to you after you have worked hard at school." - B. "Do you see your DUI as an indication that you likely have a problem with alcohol?" - C. "Your advisor obviously thinks that your beer drinking is affecting your grades, and that is why he referred you here." - D. "What else could be causing your low grades then?" Pause. Answer: A. Why correct: Option A uses **motivational interviewing** by delivering an empathetic, non-judgmental reflective response that validates Marcus's desire to relax, lowering resistance and strengthening the therapeutic alliance. Why distractors fail: - B. Option B is incorrect because asking a closed-ended, confronting question about his DUI forces the patient into a defensive posture when he is still in **denial**. - C. Option C is incorrect because citing external pressure from an advisor bypasses the patient's internal perspective and creates an adversarial dynamic. - D. Option D is incorrect because asking an argumentative, challenging question invites debate rather than exploring ambivalence. Active Recall Checkpoints. 1. What key feature distinguishes **physical dependence** from **psychological dependence**? 2. How does **denial** manifest during a clinical psychiatric interview for **alcohol use disorder**? 3. What is the sensitivity and specificity threshold for the **CAGE questionnaire** when 2 or more items are positive? 4. Why is **motivational interviewing** preferred over direct confrontation when engaging a patient in **denial**? 5. Which screening tool is most effective for identifying problem drinking in college students before **withdrawal** occurs? 💡 *Next study step:* Review the **CAGE** vs. **AUDIT** comparison and **alcohol withdrawal** management protocols in Chapter 11. Next. Topic. Review Question: Lab Interpretation. Bottom Line Summary. * **AST** is elevated greater than **ALT**, typically within 3 times the upper limit of normal (for example, AST 83 U/L and ALT 50 U/L with normal range 0 to 40 U/L). This ratio resolves within 1 to 3 months of abstinence. * Mild **macrocytosis** (elevated **MCV**, such as 105 fL with normal 80 to 96 fL) without anemia develops in 60% of heavy drinkers (3 or more drinks daily for women, 5 or more drinks daily for men) and resolves within 2 to 3 months of sobriety. * **Isolated hypertriglyceridemia** (triglycerides 325 mg/dL with normal target 150 mg/dL or less) occurs without severe cholesterol elevation and resolves within 1 to 2 months of abstinence. * **Acamprosate** is the **first-line** choice for relapse prevention in patients with liver disease because it is excreted renally, whereas **naltrexone** is contraindicated in acute hepatitis or liver failure. * **Naltrexone** blocks endogenous and exogenous opioids. It is contraindicated in patients requiring opioid analgesia for scheduled procedures or dental surgery. * The legal blood alcohol concentration limit for operating a motor vehicle in the United States is 0.08 g/dL, which is typically reached after binge drinking 4 or more drinks for women or 5 or more drinks for men within 2 hours. High-Yield Concept Review: Lab Interpretation in Alcohol Use Disorder. Clinical Interpretation of Hepatic Enzymes. In chronic heavy alcohol consumption, liver enzyme elevations show a classic pattern where **AST** is greater than **ALT**. Both enzymes usually stay within 3 times the upper limit of normal. For example, a patient may present with an **AST** of 83 U/L and an **ALT** of 50 U/L when the normal baseline is 0 to 40 U/L. This pattern reflects alcohol-induced hepatic injury [1, 2]. Upon achieving complete abstinence, these liver transaminases return to baseline within 1 to 3 months source 2. **Board trap**: Do not confuse alcohol-induced transaminase elevation with viral or non-alcoholic liver disease. In viral hepatitis or non-alcoholic fatty liver disease, **ALT** is greater than **AST** source 3. When **AST** exceeds **ALT**, think alcohol, statin use, or acetaminophen source 3. Hematologic Findings and Erythrocyte Indices. Heavy alcohol consumption causes a direct toxic effect on erythropoiesis, resulting in mild **macrocytosis** without anemia [4, 5]. The mean corpuscular volume, or **MCV**, elevates above the normal range of 80 to 96 fL, often reaching 105 fL, while hemoglobin and hematocrit remain completely normal (for example, hemoglobin 15 g/dL and hematocrit 45%) source 5. This finding occurs in approximately 60% of individuals who engage in regular heavy drinking, defined as 3 or more drinks daily for women or 5 or more drinks daily for men source 4. Normal erythrocyte size restores within 2 to 3 months of sustained sobriety as new red blood cells generate source 4. **Safety alert**: When evaluating macrocytic red blood cell indices in a patient with substance use, always verify whether true megaloblastic anemia is present from folate or vitamin B12 deficiency. Isolated alcohol-induced **macrocytosis** presents with normal hemoglobin levels, whereas nutritional deficiencies produce true anemia source 5. Lipid Profiles and Metabolic Markers. Chronic alcohol intake frequently produces **isolated hypertriglyceridemia** [6, 7]. Serum triglycerides elevate significantly, often reaching levels such as 325 mg/dL when the desirable target is 150 mg/dL or less source 7. High-density lipoprotein (**HDL**) and low-density lipoprotein (**LDL**) typically remain near normal limits (for example, HDL 58 mg/dL and LDL 120 mg/dL) [6, 7]. This isolated lipid surge clears within 1 to 2 months of complete abstinence source 6. Integrating Lab Findings into Relapse Prevention. Laboratory markers serve as objective biological indicators to monitor treatment progress and confirm sobriety over time source 8. When selecting pharmacotherapy for relapse prevention based on lab profiles: * **First-line** treatment for a patient with elevated transaminases or established liver disease is **acamprosate**, which acts on **GABA** and **glutamate** pathways and is excreted by the kidneys [9, 10]. * **Naltrexone** reduces alcohol cravings by blocking endogenous opioids, but it carries a **Safety alert** because it is contraindicated in acute hepatitis, liver failure, or in patients taking prescribed opioids source 11. Sample Board Review Questions. Question 1. A 58-year-old man with a 10-year history of heavy alcohol use presents for an annual health evaluation source 1. Laboratory testing reveals AST 83 U/L (normal 0 to 40 U/L), ALT 50 U/L (normal 0 to 40 U/L), Hemoglobin 15 g/dL, Hematocrit 45%, MCV 105 fL (normal 80 to 96 fL), and Triglycerides 325 mg/dL (normal 150 mg/dL or less) [2, 5, 7]. He asks how long it will take for his lab values to normalize if he maintains complete abstinence. What is the correct clinical teaching? A) All laboratory abnormalities will normalize within 1 week of stopping alcohol. B) Transaminases normalize in 1 to 3 months, macrocytosis resolves in 2 to 3 months, and hypertriglyceridemia resolves in 1 to 2 months. C) Macrocytosis is permanent and indicates irreversible bone marrow failure. D) Triglycerides will continue to rise for 6 months after alcohol cessation. Pause. Answer. **Best Answer:** B [2, 4, 6] **Why It Is Correct:** In chronic alcohol use, elevated **AST** over **ALT** normalizes within 1 to 3 months of sobriety source 2. Mild **macrocytosis** without anemia (elevated **MCV**) resolves within 2 to 3 months as new red blood cells are produced source 4. **Isolated hypertriglyceridemia** clears within 1 to 2 months of abstinence source 6. **Why the Other Choices Are Wrong:** * **A:** One week is too short for red blood cell turnover or hepatic transaminase clearance source 4. * **C:** Alcohol-induced macrocytosis is fully reversible with 2 to 3 months of sustained sobriety source 4. * **D:** Triglycerides decrease back toward normal levels within 1 to 2 months of abstinence, rather than continuing to rise source 6. Question 2. A 54-year-old man with moderate liver disease and a history of alcohol use disorder reports severe recent life stressors, including job loss and the death of a sibling [12, 13]. He has been abstinent for 3.5 years but reports strong, increasing urges to drink source 13. Which medication is the most appropriate first-line choice to prevent relapse in this patient? A) Naltrexone B) Disulfiram C) Acamprosate D) Lorazepam Pause. Answer. **Best Answer:** C [10, 14] **Why It Is Correct:** **Acamprosate** is the **first-line** pharmacotherapy for relapse prevention in patients with underlying liver disease because it is cleared by the kidneys and does not undergo hepatic metabolism [9, 10]. **Why the Other Choices Are Wrong:** * **A:** **Naltrexone** is contraindicated in patients with acute hepatitis or significant liver failure due to potential hepatotoxicity [10, 11]. * **B:** **Disulfiram** is an aversion therapy that is not recommended as initial therapy and requires extreme caution in liver disease source 15. * **D:** **Lorazepam** is a benzodiazepine used for acute alcohol withdrawal, not for long-term relapse prevention or craving management in an outpatient setting [10, 16]. Question 3. A 44-year-old woman in recovery for alcohol and methamphetamine dependence is preparing for discharge from a residential facility source 17. She plans to begin extensive dental reconstruction involving oral surgery next month source 18. Which medication is contraindicated for her alcohol relapse prevention plan? A) Acamprosate B) Naltrexone C) Disulfiram D) Topiramate Pause. Answer. **Best Answer:** B [18, 19] **Why It Is Correct:** **Naltrexone** blocks mu-opioid receptors [11, 20]. It is contraindicated in patients who will require opioid analgesics for anticipated surgical or dental procedures, as it blocks opioid efficacy and can precipitate acute withdrawal if opioids are administered [11, 19]. **Why the Other Choices Are Wrong:** * **A:** **Acamprosate** does not interact with opioid receptors and can be safely used alongside surgical analgesics [9, 19]. * **C:** **Disulfiram** causes noxious reactions with alcohol exposure but does not block opioid pain medications [15, 19]. * **D:** **Topiramate** modulates GABA and glutamate without interfering with opioid analgesia source 21. 💡 **Next Study Step:** Review Chapter 11 withdrawal protocols (CIWA-Ar and COWS) and pharmacotherapy for opioid use disorder (buprenorphine vs naltrexone vs methadone) to master all substance-related emergency and maintenance algorithms. Next. End of this drive.